This study evaluates the cost-effectiveness and budget impact to US payers of point-of-care nucleic acid amplification tests (NAAT) for group A streptococcus. Objectives: In the United States, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback